Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1984 Dec;43(6):819–824. doi: 10.1136/ard.43.6.819

Characterisation of centromere (kinetochore) antigen reactive with sera of patients with a scleroderma variant (CREST syndrome).

M Nishikai, Y Okano, H Yamashita, M Watanabe
PMCID: PMC1001545  PMID: 6524984

Abstract

Anticentromere (kinetochore) antibody is the marker antibody in CREST syndrome, but the precise molecular composition of the partner antigen has been poorly defined. This report describes for the first time a procedure for the successful extraction and biochemical characterisation of the centromere antigen molecule. The centromere antigen was extracted with 4M NaCl solution. The molecular weight of the partner antigen of the centromere antibody was determined to be 70 000 daltons by the SDS-PAGE and immunoblotting methods. A Sephacryl S-300 column experiment confirmed these results. Centromere antigenic activity was preserved at pHs between 3 and 11 and was resistant to three enzymes, trypsin, RNase, and DNase.

Full text

PDF
819

Images in this article

821Image
on p.821
821Image
on p.821
822Image
on p.822
823Image
on p.823

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alspaugh M. A., Tan E. M. Antibodies to cellular antigens in Sjögren's syndrome. J Clin Invest. 1975 May;55(5):1067–1073. doi: 10.1172/JCI108007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark G., Reichlin M., Tomasi T. B., Jr Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus. J Immunol. 1969 Jan;102(1):117–122. [PubMed] [Google Scholar]
  3. Douvas A. S., Achten M., Tan E. M. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem. 1979 Oct 25;254(20):10514–10522. [PubMed] [Google Scholar]
  4. Fritzler M. J., Kinsella T. D. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980 Oct;69(4):520–526. doi: 10.1016/0002-9343(80)90462-3. [DOI] [PubMed] [Google Scholar]
  5. Habets W. J., de Rooij D. J., Salden M. H., Verhagen A. P., van Eekelen C. A., van de Putte L. B., van Venrooij W. J. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol. 1983 Oct;54(1):265–276. [PMC free article] [PubMed] [Google Scholar]
  6. Kallenberg C. G., Pastoor G. W., Wouda A. A., The T. H. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982 Aug;41(4):382–387. doi: 10.1136/ard.41.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mattioli M., Reichlin M. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol. 1971 Nov;107(5):1281–1290. [PubMed] [Google Scholar]
  8. Mattioli M., Reichlin M. Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen. Arthritis Rheum. 1974 Jul-Aug;17(4):421–429. doi: 10.1002/art.1780170413. [DOI] [PubMed] [Google Scholar]
  9. McCarty G. A., Rice J. R., Bembe M. L., Barada F. A., Jr Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum. 1983 Jan;26(1):1–7. doi: 10.1002/art.1780260101. [DOI] [PubMed] [Google Scholar]
  10. McKeon F. D., Tuffanelli D. L., Fukuyama K., Kirschner M. W. Autoimmune response directed against conserved determinants of nuclear envelope proteins in a patient with linear scleroderma. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4374–4378. doi: 10.1073/pnas.80.14.4374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mimori T., Akizuki M., Yamagata H., Inada S., Yoshida S., Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 1981 Sep;68(3):611–620. doi: 10.1172/JCI110295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Miyachi K., Tan E. M. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum. 1979 Jan;22(1):87–93. doi: 10.1002/art.1780220114. [DOI] [PubMed] [Google Scholar]
  13. Miyawaki S., Kohmoto K., Kurata N., Ofuji T. Identification and characterization of two new soluble nuclear antigens reactive with sera of patients with connective tissue diseases. Arthritis Rheum. 1978 Sep-Oct;21(7):803–810. doi: 10.1002/art.1780210711. [DOI] [PubMed] [Google Scholar]
  14. Moroi Y., Hartman A. L., Nakane P. K., Tan E. M. Distribution of kinetochore (centromere) antigen in mammalian cell nuclei. J Cell Biol. 1981 Jul;90(1):254–259. doi: 10.1083/jcb.90.1.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Moroi Y., Peebles C., Fritzler M. J., Steigerwald J., Tan E. M. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1627–1631. doi: 10.1073/pnas.77.3.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nishikai M., Reichlin M. Purification and characterization of a nuclear non-histone basic protein (Mi-1) which reacts with anti-immunoglobulin sera and the sera of patients with dermatomyositis. Mol Immunol. 1980 Sep;17(9):1129–1141. doi: 10.1016/0161-5890(80)90109-1. [DOI] [PubMed] [Google Scholar]
  17. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  18. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  19. Tan E. M., Kunkel H. G. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol. 1966 Mar;96(3):464–471. [PubMed] [Google Scholar]
  20. Tojo T., Kaburaki J., Hayakawa M., Okamoto T., Tomii M., Homma M. Precipitating antibody to a soluble nuclear antigen "Ki" with specificity for systemic lupus erythematosus. Ryumachi. 1981;21 (Suppl):129–140. [PubMed] [Google Scholar]
  21. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Winn D. M., Wolfe J. F., Harmon D., Sharp G. C. Characterization of a distinct nuclear acidic protein antigen (MA) and clinical findings in systemic lupus erythematosus patients with MA antibodies. J Clin Invest. 1979 Sep;64(3):820–823. doi: 10.1172/JCI109529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wolfe J. F., Adelstein E., Sharp G. C. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest. 1977 Jan;59(1):176–178. doi: 10.1172/JCI108616. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES